嘉和生物-B(06998.HK)全年研发开支增加至6.966亿元
格隆汇 3 月 23日丨嘉和生物-B(06998.HK)发布截至2020年12月31日止年度全年业绩公告,报告期内,总收益为人民币1030万元,主要来自根据按服务收费合约向客户提供研究及制造服务。期内研发开支为人民币6.966亿元,而2019年年度则为人民币4.388亿元。有关支出主要归因于集团正在进行的临床试验开支增加及员工薪金及相关福利成本。
报告期内,全面亏损总额为人民币30.328亿元,而2019年年度则为人民币5.23亿元,主要由于根据香港财务报告准则,优先股于公司首次公开发售中转换为普通股后,集团就优先股公允价值亏损净额录得非经常性亏损人民币19.338亿元。根据非香港财务报告准则计量,报告期内,经调整亏损为人民币6.546亿元。
公司为一家正在进入商业化阶段的生物制药公司,专注于肿瘤及自身免疫药物的研发及商业化。公司于2020年10月7日成功于联交所上市并开始买卖。2020年,公司管线中候选药物的开发及业务营运取得显著进展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.